Cerity Partners LLC Makes New $656,000 Investment in Immunome, Inc. (NASDAQ:IMNM)

Cerity Partners LLC acquired a new stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 61,346 shares of the company's stock, valued at approximately $656,000. Cerity Partners LLC owned about 0.14% of Immunome at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. TD Asset Management Inc acquired a new stake in Immunome during the 3rd quarter valued at $1,063,000. Acadian Asset Management LLC acquired a new stake in Immunome during the 3rd quarter valued at $414,000. Finally, Dorsey Wright & Associates acquired a new stake in Immunome during the 3rd quarter valued at $26,000. Institutional investors and hedge funds own 44.58% of the company's stock.

Analysts Set New Price Targets

IMNM has been the subject of several research reports. Leerink Partnrs reaffirmed an "outperform" rating on shares of Immunome in a report on Monday, January 29th. Wedbush raised their price target on Immunome from $27.00 to $33.00 and gave the company an "outperform" rating in a report on Monday, April 1st. SVB Leerink began coverage on Immunome in a report on Monday, January 29th. They set an "outperform" rating and a $30.00 target price for the company. Finally, Guggenheim began coverage on Immunome in a report on Monday, April 15th. They set a "buy" rating and a $35.00 target price for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $32.67.

Immunome Price Performance

IMNM stock traded down $0.39 during midday trading on Wednesday, reaching $14.27. The company had a trading volume of 555,442 shares, compared to its average volume of 725,235. The company has a market capitalization of $851.78 million, a price-to-earnings ratio of -2.68 and a beta of 1.66. The stock has a 50 day moving average price of $22.56 and a 200-day moving average price of $15.07. Immunome, Inc. has a 1-year low of $4.44 and a 1-year high of $30.96.

Immunome (NASDAQ:IMNM - Get Free Report) last issued its earnings results on Thursday, March 28th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.26). The business had revenue of $3.83 million for the quarter, compared to analyst estimates of $3.40 million. Immunome had a negative return on equity of 69.74% and a negative net margin of 761.92%. As a group, research analysts anticipate that Immunome, Inc. will post -1.91 earnings per share for the current year.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.